They detected EGFRvIII in 39.5% of tumour tissue samples and in 44.7% of their paired serum exosome samples, whereas 28.1% of tumour biopsy samples had EGFR and EGFRvIII co-expression. This evidence concerns the gene EGFR and neoplasm.